News
-
Diabetes Drug Shows Promise Against Parkinson’s Disease
(August 7, 2017) – A new promising clinical trial has suggested that a drug that is normally used to control type-2 diabetes may also play a crucial role in halting the progression of Parkinson’s disease. Read more…
-
The 23rd Parkinson’s Unity Walk Raised Over $1.5 Million in Donations for Parkinson’s Disease Research
KINGSTON, N.J. (July 27, 2017) – The Parkinson Alliance announced today that the 23rd Parkinson’s Unity Walk, which took place on Saturday, April 22, 2017, raised over $1.5 million in donations for Parkinson’s disease research. Thanks to th …
-
The Michael J. Fox Foundation Announces Award to Drive Phase IIa Clinical Trial Investigating Potential Safety and Benefit of Nilotinib in PD
(July 28, 2017) – The Michael J. Fox Foundation for Parkinson’s Research today announced U.S. Food and Drug Administration (FDA) approval of a multicenter, double-blind, randomized, placebo-controlled Phase IIa clinical trial to test safety and tolerab …
-
Forbes Includes Acadia, Maker of Nuplazid on List of Most Innovative Growth Companies
(July 27, 2017) – Acadia Pharmaceuticals, the maker of Nuplazid (pimavanserin), an oral medication to treat hallucinations and delusions associated with Parkinson’s disease (PD), was ranked 11th on Forbes Magazine’s 2017 list of the “ …
-
Mitsubishi Buys Israel’s NeuroDerm for $1.1B
(July 24, 2017) – Japan’s Mitsubishi Tanabe Pharma has boosted its pipeline with a $1.1B deal to buy NeuroDerm, an Israeli developer of central nervous system therapies. The will see NeuroDerm merged with Mitsubishi’s Israeli unit to become a wholly-ow …
-
Participants Invited to Take Survey on Vision and Parkinson’s Disease
The vision survey is now closed. After the data is analyzed, the results will be published in report form. (July 12, 2017)—The Parkinson Alliance invites people living with Parkinson’s disease (PD) to participate in our survey-based research project en …
-
US WorldMeds is Now Distributing XADAGO® (Safinamide) in the U.S. for PD Patients
(July 11, 2017) – Alliance partners Newron Pharmaceuticals S.p.A. and Zambon S.p.A. based in Milan, and Louisville-based US WorldMeds announced today that XADAGO (safinamide) is now available as an add-on therapy for U.S. patients w …
-
Acorda Submits New Drug Application to U.S. Food and Drug Administration for CVT-301
(July 7, 2017) – Acorda Therapeutics, Inc.has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for INBRIJATM (CVT-301, levodopa inhalation powder). Acorda is developing INBRIJA as a treatment for symptoms of OFF per …
-
Study Suggests CLR01 May Improve Symptoms of Early Parkinson’s
(July 7, 2017) – Treatment with a drug called CLR01 improved balance and movement coordination in mice with early stage Parkinson’s disease, according to results of a new preclinical study. Researchers said CLR01 acts by decreasing the amou …
-
Global Kinetics Launching Large Randomized Study of Wearable for Parkinson’s Disease
(July 7, 2017) – Global Kinetics Corporation, a digital health company from Australia that makes tech for people with Parkinson’s disease (PD), announced new sets of data gleaned from reports of PD patients who use their product. They’ve al …